ClinicalTrials.gg
CompletedNCT02207400Updated Jul 31, 2018Results posted

To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms

A Phase 2 interventional study of Sodium bicarbonate and sodium fluoride and Sodium fluoride in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-31.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Salus Research, Inc. Participants will be recruited from their database and by use of an external recruitment agency

Read the detailed description

This study will be a single-centre, examiner blind, two treatment, parallel group, stratified (by baseline number of bleeding sites smoking status and bacterial sampling) randomized clinical study. At the screening visit, following provision of written informed consent, eligible participants will be provided with a standard toothpaste and toothbrush for brushing once in at the clinic and for approximately one week use at home until the baseline visit. Participants will be asked to abstain from brushing over a 12 hour period prior to the Baseline visit. At the baseline visit an oral soft tissue (OST) assessment, Modified Gingival Index (MGI) and Bleeding Index (BI), and then dental plaque assessment will be performed. Participants will be stratified according to their baseline number of bleeding sites, smoking status and whether selected for bacterial sampling. Participants will be then randomized into one of two treatment groups. After using, their assigned treatment twice daily at home for 6 weeks (visit 3), 12 weeks (visit 4) and 24 weeks (visit 5), participants will return to the site with overnight plaque at approximately the same time of day as the Baseline visit if possible. Participants will undergo a full OST examination and the recording of any Adverse Events (AEs). Participants will then undergo MGI, BI followed by dental plaque assessment. Microbiological samples will be collected on a subset of 50 participants (Determined by first 50 participants randomized).

02

Conditions studied

  • Oral Hygiene
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or oral/dental examination.
  • A minimum of 20 permanent gradable teeth
  • Moderate gingivitis present at the screening visit in the opinion of the investigator
  • A total of 20 bleeding sites or greater at baseline visit
  • Positive response to bleeding on brushing present at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding women
  • Tobacco chewers
  • Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participant or undermines the data validity.
  • Recent history (within the last year) of alcohol or other substance abuse
  • Participants requiring prophylactic antibiotic treatment prior to dental therapy
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients
  • Have current active caries or any medical conditions which may directly influence gingival bleeding
  • Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations
  • Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index
  • Participation in another clinical study or receipt of an drug or oral care product within 30 days of the screening visit
  • An employee of the sponsor or the study site or members or their immediate family.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Experimental Dentifrice

    Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride

    Drug: Sodium bicarbonate and sodium fluoride

  • Active comparator
    Reference Dentifrice

    Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride

    Drug: Sodium fluoride

Interventions

  • DrugSodium bicarbonate and sodium fluoride

    Drug pages: Sodium Bicarbonate · Sodium Fluoride

    Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride

  • Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride

06

What researchers measure

Primary outcomes

  1. Number of Gingival Bleeding Sites at 24 Weeks

    The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

    Time frame: 24 weeks

  2. Modified Gingival Index (MGI) at 24 Weeks

    MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: 24 weeks

Secondary outcomes

  1. Number of Gingival Bleeding Sites at 6 and 12 Weeks

    BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

    Time frame: Baseline, 6 and 12 weeks

  2. Modified Gingival Index (MGI)) at 6 and 12 Weeks.

    MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: 6 and 12 weeks

  3. Bleeding Index (BI) at 6, 12 and 24 Weeks

    BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

    Time frame: 6, 12 and 24 weeks

  4. Plaque Control (Overall and Interproximal Dental Plaque Scores) at 6, 12 and 24 Weeks.

    The dental examiner had used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. Interproximal Dental Plaque Scores were analyzed in the same way as for Overall scores but just based on mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth.

    Time frame: 6, 12 and 24 weeks

  5. Bacterial Count at Baseline, After 6, 12, 24 and 32 Weeks

    Microbiological samples were collected at baseline, 6 weeks, 12 weeks, 24 weeks and 32 weeks. Plaque was harvested from contra-lateral 1st molar teeth, where no restorations are present, using a sterile paper point. The paper point was immersed into 4 ml of Calgon Ringer's solution in a sterile bijou and kept on ice until they can be taken to the laboratory for processing (within 24 hours).

    Time frame: Baseline, 6, 12, 24 and 32 weeks

07

Results

Posted Jul 26, 2016

Participant flow

The participants were recruited at a clinical site in the USA.

Participant flow — Overall Study
MilestoneSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Started123123
Completed107109
Not completed1614
Withdrew: Adverse event11
Withdrew: Lost to follow-up67
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject84
Withdrew: Positive urine pregnancy test01

Outcome measures

PrimaryNumber of Gingival Bleeding Sites at 24 Weeks

The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

Time frame:
24 weeks
Reported as:
Mean · Number of bleeding sites
Number of Gingival Bleeding Sites at 24 Weeks
Number of bleeding sitesSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Number of Gingival Bleeding Sites at 24 Weeks13.24 ± 7.66324.90 ± 9.044
Statistical analysis
  • Sodium Bicarbonate and Sodium Fluoride Dentifrice vs Sodium Fluoride Dentifrice · ANCOVA · p = <0.0001 · Adjusted mean difference: -11.612 · 95% CI -13.191 to -10.033Difference is Sodium Bicarbonate and Sodium Fluoride Dentifrice minus Sodium Fluoride Dentifrice such that a negative difference favors the first named treatment.
PrimaryModified Gingival Index (MGI) at 24 Weeks

MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame:
24 weeks
Reported as:
Mean · Units on a scale
Modified Gingival Index (MGI) at 24 Weeks
Units on a scaleSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Modified Gingival Index (MGI) at 24 Weeks1.26 ± 0.5051.93 ± 0.408
Statistical analysis
  • Sodium Bicarbonate and Sodium Fluoride Dentifrice vs Sodium Fluoride Dentifrice · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.652 · 95% CI -0.738 to -0.566Difference is Sodium Bicarbonate and Sodium Fluoride Dentifrice minus Sodium Fluoride Dentifrice such that a negative difference favors the first named treatment.
SecondaryNumber of Gingival Bleeding Sites at 6 and 12 Weeks

BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

Time frame:
Baseline, 6 and 12 weeks
Reported as:
Mean · Number of bleeding sites
Number of Gingival Bleeding Sites at 6 and 12 Weeks
Number of bleeding sitesSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Number of Bleeding Sites at Baseline29.76 ± 8.23829.05 ± 8.390
Number of Bleeding Sites at 6 weeks12.26 ± 9.33923.23 ± 10.993
Number of Bleeding Sites at 12 weeks15.73 ± 7.63223.86 ± 9.265
SecondaryModified Gingival Index (MGI)) at 6 and 12 Weeks.

MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame:
6 and 12 weeks
Reported as:
Mean · Units on a scale
Modified Gingival Index (MGI)) at 6 and 12 Weeks.
Units on a scaleSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
MGI at 6 weeks1.50 ± 0.5671.96 ± 0.427
MGI at 12 weeks1.50 ± 0.5361.94 ± 0.464
SecondaryBleeding Index (BI) at 6, 12 and 24 Weeks

BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

Time frame:
6, 12 and 24 weeks
Reported as:
Mean · Units on a Scale
Bleeding Index (BI) at 6, 12 and 24 Weeks
Units on a ScaleSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
BI Score Score at 6 weeks0.15 ± 0.1330.30 ± 0.172
BI Score Score at 12 weeks0.19 ± 0.1120.28 ± 0.135
BI Score Score at 24 weeks0.17 ± 0.1160.31 ± 0.159
SecondaryPlaque Control (Overall and Interproximal Dental Plaque Scores) at 6, 12 and 24 Weeks.

The dental examiner had used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. Interproximal Dental Plaque Scores were analyzed in the same way as for Overall scores but just based on mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth.

Time frame:
6, 12 and 24 weeks
Reported as:
Mean · Units on a scale
Plaque Control (Overall and Interproximal Dental Plaque Scores) at 6, 12 and 24 Weeks.
Units on a scaleSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Overall Plaque Score at 6 weeks2.56 ± 0.5363.01 ± 0.411
Overall Plaque Score at 12 weeks2.54 ± 0.4952.90 ± 0.374
Overall Plaque Score at 24 weeks2.47 ± 0.4372.92 ± 0.399
Interproximal Plaque Score at 6 weeks2.78 ± 0.4923.19 ± 0.351
Interproximal Plaque Score at 12 weeks2.76 ± 0.4373.10 ± 0.311
Interproximal Plaque Score at 24 weeks2.71 ± 0.3903.11 ± 0.336
SecondaryBacterial Count at Baseline, After 6, 12, 24 and 32 Weeks

Microbiological samples were collected at baseline, 6 weeks, 12 weeks, 24 weeks and 32 weeks. Plaque was harvested from contra-lateral 1st molar teeth, where no restorations are present, using a sterile paper point. The paper point was immersed into 4 ml of Calgon Ringer's solution in a sterile bijou and kept on ice until they can be taken to the laboratory for processing (within 24 hours).

Time frame:
Baseline, 6, 12, 24 and 32 weeks
Reported as:
Mean · colony forming units per sample
Bacterial Count at Baseline, After 6, 12, 24 and 32 Weeks
colony forming units per sampleSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
Staph Count at Baseline (n=24, 26)0.2 ± 0.820.2 ± 0.86
Steph Count at 6 weeks (n=24, 26)0.1 ± 0.340 ± 0.20
Steph Count at 12 weeks (n=24, 26)1.8 ± 7.103.2 ± 15.47
Steph Count at 24 weeks (n=23, 25)0.6 ± 1.590.2 ± 0.37
Steph Count at 32 weeks (n=21, 21)0.2 ± 0.510.1 ± 0.36
Yeast Count at Baseline (n=24, 26)203.4 ± 842.28647.8 ± 2958.78
Yeast Count at 6 weeks (n=23, 26)287.3 ± 1014.31784.3 ± 1796.75
Yeast Count at 12 weeks (n=24, 25)668.9 ± 812.81411.3 ± 906.19
Yeast Count at 24 weeks (n=17, 22)1479.6 ± 1165.481522.3 ± 1008.13
Yeast Count at 32 weeks (n= 14, 14)2743.5 ± 2505.751206.4 ± 1008.34
Coliform count at Baseline (n= 24, 26)3.9 ± 8.823.8 ± 8.27
Coliform count at 6 weeks (n= 24, 26)2.6 ± 6.725.7 ± 20.05
Coliform count at 12 weeks (n= 24, 26)10.9 ± 14.6526.9 ± 78.47
Coliform count at 24 weeks (n=23, 25)8.1 ± 16.8612.6 ± 19.24
Coliform count at 32 weeks (n=21, 21)10.9 ± 16.1717.8 ± 29.84
E. Coli count at Baseline (n=24, 26)0 ± 00 ± 0.20
E. Coli count at 6 weeks (n=24, 26)0.1 ± 0.280 ± 0.20
E. Coli count at 12 weeks (n=24, 26)0.1 ± 0.280 ± 0
E. Coli count at 24 weeks (n=23, 25)0.3 ± 1.250.2 ± 0.55
E. Coli count at 32 weeks (n=21, 21)0.6 ± 1.290 ± 0.22

Adverse events

Collected over Adverse events were collected throughout the study from the start of the washout period, until five days following last treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Bicarbonate and Sodium Fluoride Dentifrice—0/123 (0%)17/123 (13.8%)
Sodium Fluoride Dentifrice—0/123 (0%)14/123 (11.4%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventSodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride Dentifrice
MOUTH INJURYInjury, poisoning and procedural complications4/1230/123
TRAUMATIC ULCERInjury, poisoning and procedural complications0/1233/123
Cellulitis OrbitalInfections and infestations2/1230/123
PneumoniaInfections and infestations2/1230/123
Lower Respiratory Tract InfectionInfections and infestations1/1230/123
Acute sinusitisInfections and infestations0/1231/123
GASTROENTERITISInfections and infestations1/1230/123
PHARYNGITISInfections and infestations0/1231/123
PHARYNGITIS STREPTOCOCCALInfections and infestations1/1230/123
PULPITIS DENTALInfections and infestations0/1231/123

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride DentifriceTotal
Mean39.39 ± 14.28437.77 ± 12.61538.58 ± 13.473
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Bicarbonate and Sodium Fluoride DentifriceSodium Fluoride DentifriceTotal
Female7478152
Male494594
08

Study locations

1 site
  • GSK Investigational Site
    Fort Wayne, Indiana 46825, United States
09

References and documents

Publications

  • Jose A, Pratten J, Bosma ML, Milleman KR, Milleman JL, Wang N. Six-Month Evaluation of a Sodium Bicarbonate-Containing Toothpaste for Reduction of Established Gingivitis: A Randomized USA-Based Clinical Trial. J Clin Dent. 2018 Mar;29(1):33-39. PubMed 29758155 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Feb 2015, 5 months.

Results were first posted in Jul 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Aug 4, 2014
StartActual
Aug 25, 2014
Primary completionActual
Feb 1, 2015
CompletionActual
Apr 30, 2015
Results first posted
Jul 26, 2016
Last update
Jul 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02207400
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 4, 2014
Start date
Aug 25, 2014
Primary completion
Feb 1, 2015
Completion
Apr 30, 2015
Results posted
Jul 26, 2016
Last update
Jul 31, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium Bicarbonate · Sodium Fluoride

Start the discussion